Biovest reports 95% of patients trated with BiovaxID still alive after 9.2 years

New York, June 7 - Biovest International reported that a long-term follow up study found that 95% of patients suffering from follicular lymphoma who were treated with BiovaxID in a phase 2 trial were still alive after 9.2 years. Forty-five percent of the patients were disease free.

The findings were presented to the American Society for Clinical Oncology annual meeting.

In addition, the study showed that 53% of patients who achieved molecular remission remained in clinical remission - they were clinically disease free - 9.2 years later. For patients who did not achieve molecular remission, none were disease free at the follow up time.

Biovest recently received agreement from the Food and Drug Administration to use patient data for the marker as a secondary endpoint of efficacy in its ongoing phase 3 trial.

Biovest is a Worcester, Mass., company developing individualized immunotherapies for life-threatening cancers of the blood system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.